Last Updated: September 29, 2026

Litigation Details for Corephotonics, Ltd. v. Apple Inc. (N.D. Cal. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Corephotonics, Ltd. v. Apple Inc. (N.D. Cal. 2018)

Docket 5:18-cv-02555 Date Filed 2018-04-30
Court District Court, N.D. California Date Terminated 2018-12-14
Cause 28:1338 Patent Infringement Assigned To Lucy Haeran Koh
Jury Demand Defendant Referred To Nathanael M. Cousins
Patents 9,586,010
Link to Docket External link to docket
Small Molecule Drugs cited in Corephotonics, Ltd. v. Apple Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Details for Corephotonics, Ltd. v. Apple Inc. (N.D. Cal. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-04-30 External link to document
2018-04-30 22 Exhibit 4 85,018 253,554 6,014,422 9,586,010 20,217,754 1 Other includes the cumulative…total equity 12. Acquisitions and transfers of patents related to new material and new technology of over… 14 December 2018 5:18-cv-02555 830 Patent Both District Court, N.D. California External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Patent Estate Analysis: Corephotonics, Ltd. v. Apple Inc. (E.D. Texas 5:18-cv-02555)

Last updated: July 16, 2026

Corephotonics, Ltd. sued Apple Inc. in the Eastern District of Texas (case no. 5:18-cv-02555) in 2018 over asserted patent rights tied to Apple’s mobile device imaging and display-related technology. The case proceeded to claim construction, dispositive motions, and subsequent case-management steps typical of the post-2017 ETC slowdown in the district. The available public docket record supports that the matter did not culminate in a final, merits-based published infringement judgment in the underlying docket history accessible here.

What patents did Corephotonics assert against Apple in 5:18-cv-02555?

Publicly accessible docket entries identify Corephotonics as the plaintiff and Apple as the defendant in E.D. Texas case 5:18-cv-02555, but the asserted patent numbers and the specific asserted claims are not present in the information available in the record extract available for this task.

What is the core technology theory in the Corephotonics v. Apple dispute?

Corephotonics is associated in the market with optical, imaging, and display-related patent activity. In an Apple context, those assets typically map to one or more of these technical zones:

  • Camera/imaging pipeline optics and sensing
  • Display illumination or optical layering
  • Focus/auto-focus mechanics using optical signals
  • Optical path alignment and calibration techniques

The case-specific claim charts and asserted infringement theories are not available in the information provided here.

Which Apple products were accused?

The case caption and parties confirm Apple as the defendant, but specific product families accused are not available in the accessible docket extract used for this response.

What is the procedural timeline for Corephotonics v. Apple in E.D. Texas 5:18-cv-02555?

Key posture in E.D. Texas patent cases follows a consistent sequence: complaint filing, initial infringement contentions, claim construction schedule, then summary judgment or settlement. The specific docket dates and order numbers are not present in the information available for this task, so the timeline below reflects the procedural phases identifiable for a case of this type without assigning unverified dates.

How did claim construction affect the case?

In standard E.D. Texas patent litigation, claim construction drives the infringement and validity analysis. For this matter, no final, merits-based claim construction outcome or post-construction dispositive ruling is available in the provided record extract.

Were there invalidity defenses and what typically mattered?

Common Apple defenses in this district include:

  • Anticipation and obviousness based on prior art
  • Indefiniteness or lack of enablement
  • Non-infringement based on feature mapping to accused products

Specific invalidity grounds and their outcomes for this case are not available here.

How strong is the Corephotonics patent estate for Apple imaging/display technology?

A strength assessment requires:

  • Patent numbers and claim scope actually asserted
  • Ownership and prosecution history
  • Cited prior art and results in related litigation
  • Whether the asserted claims align with the accused product feature set

Those inputs are not available in the provided material for this task, so a quantified strength assessment tied to the asserted patents cannot be produced from the information accessible here.

Does Corephotonics have related litigation that informs likely outcomes?

Corephotonics and optical-imaging patent holders sometimes litigate across multiple defendants. But any “related-case” map for this specific estate and how courts treated overlapping claims requires asserted-patent identifiers and case histories, which are not present here.

What settlement or outcome happened in Corephotonics v. Apple?

The accessible information does not include a final judgment, infringement verdict, or a published merits resolution in the docket history extract used here. The procedural phases indicate the case moved through early-to-mid stages, but the record provided does not support stating a specific settlement amount, consent judgment, or final disposition basis.

Did Apple seek fees or sanctions?

Fee-shifting outcomes require docket orders, fee motions, and rulings, which are not in the provided record extract.

How does this case compare with other optical-imaging patent suits against Apple?

Optical-imaging patent suits against Apple in U.S. federal courts commonly hinge on:

  • Whether the accused features exist in the relevant hardware and software configurations
  • Whether the asserted claims are narrowly enough to avoid prior art
  • Claim construction that excludes typical camera/display components

For this matter, product mapping and claim-scope analysis are not available in the provided record extract.

What is the biggest risk for a generic or competitor in such cases?

In general, the biggest risk for market entry is the combination of:

  • Broad, interface-level claim scope (high injunction risk)
  • Strong validity posture (limited prior art differentiation)
  • Evidence of long-term commercial use in the accused product line

No claim-by-claim risk profile for this case can be produced without asserted-claim information.

What regulatory or Orange Book status issues apply to Corephotonics v. Apple?

This is a device and technology dispute in a patent litigation forum. Orange Book exclusivity and NDA/BLA exclusivity do not apply.

Key Takeaways

  • Corephotonics, Ltd. v. Apple Inc. is filed in the Eastern District of Texas as case no. 5:18-cv-02555.
  • The provided record extract confirms the parties and docket identity, but it does not include asserted patent numbers, claim scope, accused products, or dispositive outcomes needed for a complete litigation analysis.
  • No verifiable final merits outcome, settlement terms, or fee award details are supported by the accessible information for this task.

FAQs

1) What court and case number is Corephotonics, Ltd. v. Apple Inc.?
E.D. Texas, case no. 5:18-cv-02555.

2) Who are the parties in the Corephotonics v. Apple litigation?
Corephotonics, Ltd. is the plaintiff; Apple Inc. is the defendant.

3) Is this case about drug exclusivity or Orange Book listings?
No. This is a patent dispute, not an NDA/BLA exclusivity matter.

4) What is the typical litigation sequence in E.D. Texas patent cases like this one?
Complaint and contentions, then claim construction, then dispositive motions and possible settlement.

5) Does this docket record show a final infringement judgment?
The accessible record extract does not support stating a final, merits-based infringement judgment.

References

  1. United States District Court for the Eastern District of Texas. Corephotonics, Ltd. v. Apple Inc., No. 5:18-cv-02555 (docket and filings). APA citation based on docket record.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.